BACKGROUND: Common reasons for elective screening and surveillance colonoscopy, at predetermined intervals, are family or personal history of colorectal cancer (CRC) or advanced adenoma (AAP). Quantified, human haemoglobin (Hb)-specific, immunochemical faecal occult blood tests (I-FOBT) detect bleeding. AIM: To determine I-FOBT sensitivity for CRC or AAP before elective colonoscopy in patients at high-risk of cancer or advanced adenoma. METHODS: Prospective double-blind study of 1000 ambulatory asymptomatic high-risk patients (555 family history of CRC, 445 surveillance for past neoplasm), who prepared three I-FOBTs before elective colonoscopy. I-FOBTs quantified as ngHb/mL of buffer by OC-MICRO instrument and results >or=50 ngHb/mL considered positive. RESULTS: At colonoscopy, eight patients had CRC, 64 others had AAP. Sensitivity for CRC and/or AAP was the highest, 65.3% (95% CI 54.3, 76.3), when any of the three I-FOBTs was >or=50 ngHb (15.4%), with specificity of 87.5% (95% CI 86.4, 90.5) identifying all CRCs and 62% of AAPs. CONCLUSIONS: All cancers or an AAP were detected every third I-FOBT-positive colonoscopy (47/154), so colonoscopy was potentially not needed at this time in 84.6% (846 patients). I-FOBT screening might provide effective supervision of high-risk patients, delaying unnecessary elective colonoscopies. This favourable evaluation needs confirmation and cost-benefit study by risk-group.
BACKGROUND: Common reasons for elective screening and surveillance colonoscopy, at predetermined intervals, are family or personal history of colorectal cancer (CRC) or advanced adenoma (AAP). Quantified, human haemoglobin (Hb)-specific, immunochemical faecal occult blood tests (I-FOBT) detect bleeding. AIM: To determine I-FOBT sensitivity for CRC or AAP before elective colonoscopy in patients at high-risk of cancer or advanced adenoma. METHODS: Prospective double-blind study of 1000 ambulatory asymptomatic high-risk patients (555 family history of CRC, 445 surveillance for past neoplasm), who prepared three I-FOBTs before elective colonoscopy. I-FOBTs quantified as ngHb/mL of buffer by OC-MICRO instrument and results >or=50 ngHb/mL considered positive. RESULTS: At colonoscopy, eight patients had CRC, 64 others had AAP. Sensitivity for CRC and/or AAP was the highest, 65.3% (95% CI 54.3, 76.3), when any of the three I-FOBTs was >or=50 ngHb (15.4%), with specificity of 87.5% (95% CI 86.4, 90.5) identifying all CRCs and 62% of AAPs. CONCLUSIONS: All cancers or an AAP were detected every third I-FOBT-positive colonoscopy (47/154), so colonoscopy was potentially not needed at this time in 84.6% (846 patients). I-FOBT screening might provide effective supervision of high-risk patients, delaying unnecessary elective colonoscopies. This favourable evaluation needs confirmation and cost-benefit study by risk-group.
Authors: Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal Journal: World J Clin Oncol Date: 2011-06-10
Authors: Loretta De Chiara; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; Oscar J Cordero; David Martínez-Ares; María Páez de la Cadena Journal: BMC Cancer Date: 2010-06-28 Impact factor: 4.430
Authors: Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer; Annekatrien C T M Depla; Pieter Scholten; Ruud J L F Loffeld; Veerle M H Coupé; Chris J J Mulder Journal: BMC Gastroenterol Date: 2012-07-24 Impact factor: 3.067
Authors: Craig Mowat; Jayne Digby; Judith A Strachan; Robyn Wilson; Francis A Carey; Callum G Fraser; Robert J C Steele Journal: Gut Date: 2015-08-20 Impact factor: 23.059
Authors: Amanda J Cross; Kate Wooldrage; Emma C Robbins; Ines Kralj-Hans; Eilidh MacRae; Carolyn Piggott; Iain Stenson; Aaron Prendergast; Bhavita Patel; Kevin Pack; Rosemary Howe; Nicholas Swart; Julia Snowball; Stephen W Duffy; Stephen Morris; Christian von Wagner; Stephen P Halloran; Wendy S Atkin Journal: Gut Date: 2018-12-11 Impact factor: 23.059
Authors: Jayne Digby; Shirley Cleary; Lynne Gray; Pooja Datt; David R Goudie; Robert J C Steele; Judith A Strachan; Adam Humphries; Callum G Fraser; Craig Mowat Journal: United European Gastroenterol J Date: 2020-03-16 Impact factor: 4.623
Authors: Mohd Syafiq Ismail; Olufemi Aoko; Sandeep Sihag; Eimear Connolly; Joseph Omorogbe; Serhiy Semenov; Neil O'Morain; Anthony O'Connor; Niall Breslin; Barbara Ryan; Deirdre McNamara Journal: BMJ Open Gastroenterol Date: 2020-03-31